MayoComplete Ovarian, Fallopian Tube, and Peritoneal Cancer Panel, Next-Generation Sequencing, Tumor
Use
This test is primarily used to determine if patients with ovarian, fallopian tube, and peritoneal cancer will respond to targeted therapy. It assesses the microsatellite instability (MSI) which is crucial for immunotherapy decisions. The test evaluates somatic mutations within a curated list of DNA damage response genes, including ATM, ATR, BARD1, BRCA1, BRCA2, BRIP1, CDK12, MLH1, MSH2, MSH6, PALB2, PMS2, RAD51C, and RAD51D. This information is useful for assessing prognosis, guiding treatment, and potentially determining eligibility for clinical trials.
Special Instructions
A final or preliminary pathology report is required with the specimen for the test to be performed. The report should include the patient's name, block number, tissue collection date, and source of the tissue. It is important that the specimen contains at least 20% tumor nuclei. The test requires either a tissue block, tissue slides, or cytology slides. Unused slides will not be returned.
Limitations
This test cannot differentiate between somatic and germline alterations, and further testing may be required if there is a potential hereditary risk. It does not detect multi-exon deletions, duplications, larger-scale genomic variants, or epigenetic modifications. The sensitivity of the assay is limited to detecting variants with at least a 5% mutant allele frequency. Variants observed in PMS2 exons 11-15 may originate from either PMS2 or its pseudogene PMS2CL, requiring additional testing for clarity.
New York Approved
Methodology
NGS
Biomarkers
LOINC Codes
- 105594-6
- 82939-0
- 69047-9
- 48767-8
- 31208-2
- 80398-1
- 85069-3
- 62364-5
- 18771-6
Result Turnaround Time
12-20 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Submit a formalin-fixed, paraffin-embedded tissue block with acceptable tumor tissue or slides with adequate tumor content and nuclei.
Causes for Rejection
Improper tissue treatment such as decalcification may cause assay failure.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Ambient (preferred) |